<DOC>
	<DOC>NCT00749697</DOC>
	<brief_summary>The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.</brief_summary>
	<brief_title>Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases</brief_title>
	<detailed_description>Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>age above 18 histological confirmation of the differentiated thyroid carcinoma available WHO performance score 02 metastatic sites lung and/or bone and/or nodal (radiologically measurable disease &gt; 1 cm) life expectancy &gt; 6 months patient has undergone total/near total thyroidectomy no past history of sensitivity/reaction to 1311 non iodine concentrating tumours received chemotherapy or radiotherapy in 6 weeks pregnant or breast feeding patients iodine contrast injection in last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>radioiodine</keyword>
	<keyword>differentiated thyroid cancers</keyword>
	<keyword>dosimetry</keyword>
	<keyword>metastases</keyword>
</DOC>